Type 1 diabetes mellitus is an autoimmune and inflammatory disease that was initially considered to affect only children and adolescents; however, it is now widely recognised that it can be triggered at any age [1]. This condition affects approximately 1.4 million children and adolescents [2], with a global incidence rate of 14.07 per 100,000 person-years [3].
In recent years there has been an increasing focus on precision medicine, including in diabetology [1–3]. However, many studies in this field have two limitations. First, most studies on diabetes prevention and treatment originate from high-income countries (HICs), whereas the burden of diabetes is highest and increasing most rapidly in lowand middle-income countries (LMICs) [4, 5].